论文部分内容阅读
吲哚胺2,3-双加氧酶(IDO)是一种色氨酸代谢初期的限速酶,研究表明免疫抑制剂IDO的表达可诱导肿瘤的免疫耐受,导致肿瘤无限制生长。通过回顾分析多项有关IDO在人类恶性肿瘤及中枢神经系统(CNS)肿瘤中的相关临床研究资料,研究发现抑制IDO的诱导作用会阻碍肿瘤的生长,阻断IDO经犬尿酸途径诱导的色氨酸耗竭过程会抑制肿瘤细胞增殖,同时提高肿瘤的免疫治疗效果。然而,IDO诱导的色氨酸代谢在CNS肿瘤免疫耐受中的作用机制目前尚不明确。深入研究IDO在CNS肿瘤中的免疫耐受作用机制具有重要意义,因此IDO抑制剂有望成为生物治疗脑肿瘤的重要手段之一。
Indoleamine 2,3-dioxygenase (IDO) is a rate-limiting enzyme in the early phase of tryptophan metabolism. Studies have shown that the expression of IDO, an immunosuppressive agent, can induce tumor tolerance and lead to unlimited tumor growth. By reviewing a number of relevant clinical studies of IDO in human malignancies and CNS tumors, it was found that inhibition of IDO induction inhibits tumor growth and blocks the IDA-induced chromatin Acid depletion can inhibit the proliferation of tumor cells and increase the immunotherapy of tumors. However, the role of IDO-induced tryptophan metabolism in immune tolerance of CNS tumors is unclear. In-depth study of IDO in CNS tumor immune tolerance mechanism is of great significance, so IDO inhibitors is expected to become one of the important means of biological treatment of brain tumors.